Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3737134 | 0.88 | GAA (0.38) | GAAL3MBTL1POLBHDAC1HDAC2 | |
| SCHEMBL8127072 | 0.88 | GAA (0.38) | GAAL3MBTL1POLBHDAC1HDAC2 | |
| SCHEMBL9686944 | 0.88 | GAA (0.38) | GAAL3MBTL1POLBHDAC1HDAC2 | |
| SCHEMBL11363578 | 0.88 | GAA (0.38) | GAAL3MBTL1POLBHDAC1HDAC2 | |
| SCHEMBL10752034 | 0.88 | GAA (0.38) | GAAL3MBTL1POLBHDAC1HDAC2 | |
| SCHEMBL9972674 | 0.85 | GAA (0.36) | GAAL3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL10332637 | 0.85 | GAA (0.40) | GAAL3MBTL1POLBHDAC1HDAC2 | |
| SCHEMBL10424371 | 0.85 | GAA (0.40) | GAAL3MBTL1POLBHDAC1HDAC2 | |
| SCHEMBL13953294 | 0.83 | GAA (0.40) | GAAL3MBTL1POLBHDAC1HDAC2 | |
| SCHEMBL14849507 | 0.82 | GAA (0.40) | GAAL3MBTL1POLBHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-0366641-B1 | Novel antimicrobial quinolonyl lactam esters | NORWICH EATON PHARMA (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0997466-A1 | Novel antimicrobial lactam-quinolones | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0775114-B1 | PROCESS FOR MAKING ANTIMICROBIAL COMPOUNDS | PROCTER & GAMBLE (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1993007154-A1 | PROCESS FOR MAKING ANTIMICROBIAL QUINOLONYL LACTAMS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-04-15 | — | — | WO | disclosed |
| US-5180719-A | Microbiocides | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1993-01-19 | — | — | US | disclosed |
| WO-1991016327-A1 | ANTIMICROBIAL QUINOLONYL LACTAMS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1991-10-31 | — | — | WO | disclosed |
| WO-1990004595-A1 | NOVEL ANTIMICROBIAL FLUOROQUINOLONYL CEPHEMS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1990-05-03 | — | — | WO | disclosed |
| WO-1990004594-A1 | NOVEL ANTIMICROBIAL QUINOLONYL LACTAM ESTERS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1990-05-03 | — | — | WO | disclosed |
| EP-0366193-A2 | Novel antimicrobial quinolonyl lactams | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0366640-A2 | Novel antimicrobial fluoroquinolonyl cephems | Norwich-Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0366641-A2 | Novel antimicrobial quinolonyl lactam esters | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0366189-A2 | Novel antimicrobial lactam-quinolones | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | GAA 209/4885L3MBTL1 3294/4885POLB 49/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | GAA 1181/4885L3MBTL1 2163/4885POLB 1463/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | GAA 209/4885L3MBTL1 3294/4885POLB 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.